Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, Single Dose Escalation Study to Assess the Safety and Pharmacokinetics of R-107 in Healthy Middle-Aged Volunteers

Next Previous
Trial Profile

A Phase 1a, Single Dose Escalation Study to Assess the Safety and Pharmacokinetics of R-107 in Healthy Middle-Aged Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 107 Radikal Therapeutics (Primary)
  • Indications Acute lung injury; COVID 2019 infections; COVID-19 pneumonia; Pulmonary arterial hypertension; SARS-CoV-2 sepsis
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 11 May 2021 According to a Claritas Pharmaceuticals media release, the company will complete this Phase 1 study later this year.
  • 21 Apr 2021 According to a Claritas Pharmaceuticals media release, funding for this study, at CMAX will be provided from an R&D expense refund that the Company expects to receive next month from the Australian Tax Office (the ATO).
  • 21 Apr 2021 According to a Claritas Pharmaceuticals media release, the enrollment is expected to begin in early Q3 this year, and will have a duration of two months.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top